Journal of psychopharmacology (Oxford, England)
2025
Karen P Barrios, Dean J Connolly, Jason Ferris et al.
17 citations
Ketamine's popularity has surged globally in the past decade, especially among young men. Emergency department visits due to its toxicity remain relatively rare, often linked to co-occurring use of other substances. Using data from the Global Drug Survey (GDS) 2018, this study explored the correlates associated with lifetime and past-year ketamine use, and estimated the socio-demographic...
The International journal on drug policy
2024
Leigh Coney, Amy Peacock, Aili Malm et al.
2 citations
Drug use and trading are typically social activities; however, supply through cryptomarkets can occur without any in-person social contact. People who use drugs alone may be at higher risk of experiencing harms, for example, due to lack of others who may call for emergency assistance. Alternatively, cryptomarkets may be a source of harm reduction information and drugs with better-known content...
Journal of Psychoactive Drugs
2023
Julian Urrutia, Brian T Anderson, Sean J Belouin et al.
21 citations
As individuals and communities around the world confront mounting physical, psychological, and social threats, three complimentary mind-body-spirit pathways toward health, wellbeing, and human flourishing remain underappreciated within conventional practice among the biomedical, public health, and policy communities. This paper reviews literature on psychedelic science, contemplative practices,...
Psychopharmacology
May 1, 2022
Sam Craft, Jason Ferris, Monica J Barratt et al.
19 citations
Synthetic cannabinoid receptor agonists (SCRAs) may be used as an alternative to natural cannabis; however, they may carry a greater risk of problematic use and withdrawal. This study aimed to characterise the withdrawal symptom profile of SCRAs and compare their profile of effect with high-potency herbal cannabis. Global Drug Survey data (2015 and 2016) were used to access a clinically...
Journal of Psychopharmacology
October 8, 2020
Rotem Petranker, Thomas Anderson, Larissa J. Maier et al.
57 citations
Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containing mushrooms. Despite its surging popularity, little is known about the specific intentions to start microdosing and the effects of this practice. Aims: First, we aimed to replicate previous findings regarding the subjective benefits and challenges...
April 12, 2020
Rotem Petranker, Thomas Anderson, Larissa J. Maier et al.
14 citations
preprint
Background: Microdosing psychedelics – the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushrooms – is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. Aims: This research had three main aims. First, we attempted to replicate previous findings regarding the subjective benefits...
Journal of Psychopharmacology
May 7, 2018
Balázs Szigeti, Adam Winstock, David Erritzøe et al.
17 citations
BACKGROUND: Neuroimaging studies imply that the regular use of ±3,4-methylenedioxymethamphetamine (MDMA), the major constituent of ecstasy pills, alters the brain's serotonergic system in a dose-dependent manner. However, the relevance of these findings remains unclear due to limited knowledge about the ecstasy/MDMA use pattern of real-life users. AIMS: We examined the representativeness of...
Human Psychopharmacology Clinical and Experimental
May 1, 2017
Leigh Coney, Larissa J. Maier, Jason Ferris et al.
18 citations
Abstract Objective This study aimed to describe self‐reported patterns of use and effects of lysergic acid diethylamide (LSD) analogues (AL‐LAD, 1P‐LSD, and ETH‐LAD) and the characteristics of those who use them. Methods An anonymous self‐selected online survey of people who use drugs (Global Drug Survey 2016; N = 96,894), which measured perceived drug effects of LSD and its analogues. Results...